Table 3 First-Line and Second-Line Treatment Regimens
| Regimen | Patients, n (%) | |
|---|---|---|
|
1 L therapy (n = 1003) |
2 L therapy (n = 287) | |
| Chemotherapy | ||
| Carboplatin-based doublet or triplet therapya | 499 (49.8) | 57 (19.9) |
| Carboplatin | 3 (0.3) | 0 |
| Cisplatin-based doublet or triplet therapya | 172 (17.1) | 7 (2.4) |
| Docetaxel | 5 (0.5) | 17 (5.9) |
| Docetaxel + nintedanib | 4 (0.4) | 16 (5.6) |
| Gemcitabine | 3 (0.3) | 1 (0.3) |
| Nintedanib | 0 | 1 (0.3) |
| Paclitaxel | 0 | 4 (1.4) |
| Pemetrexed | 9 (0.9) | 0 |
| Vinorelbine | 3 (0.3) | 1 (0.3) |
| Immuno-oncology therapy | ||
| Atezolizumab | 0 | 32 (11.1) |
| Nivolumab | 5 (0.5) | 20 (7.0) |
| Pembrolizumab | 174 (17.3) | 96 (33.4) |
| Targeted therapyb | ||
| Afatinib | 67 (6.7) | 5 (1.7) |
| Alectinib | 2 (0.2) | 2 (0.7) |
| Ceritinib | 6 (0.6) | 3 (1.0) |
| Crizotinib | 11 (1.1) | 4 (1.4) |
| Erlotinib | 12 (1.2) | 5 (1.7) |
| Gefitinib | 24 (2.4) | 3 (1.0) |
| Osimertinib | 4 (0.4) | 13 (4.5) |